Currently efficacy of therapy of patients with MDR Ð¢Ð’ does not exceed 48.7% worldwide and in Russian Federation. One of the reason is a frequent development of adverse drug reactions during the use of combination of antituberculosis drugs. Since 2013 after registration of tioureidoiminomethylpyridinium perchlorate (Pecrhlozon) in Russian Federation, opportunities appeared for further study of its efficacy and safety in treatment of tuberculosis with multiple drug resistance (MDR). In the present study we applied monitoring of adverse drug reactions during complex therapy by Perchlozon in combination with five other drugs with the use of international 5 grade scale. We used Common Terminology Criteria for Adverse Events (version 3.0). In the study only mild (grade 1) and moderate (grade 2) adverse drug reactions were observed except single case when severe (grade 3) adverse drug reaction happened. Mild adverse reactions that during receiving Perchlozon therapy in complex with other drugs for MDR TB did not require its cessation.